A recent study found that S100A4 expression correlates with poor patient survival in mulitple myeloma, and that S100A8 and S100A9 are markers that correlate with poor response of multiple myeloma patients to treatment with proteasome inhibitors and the histone deacetylase inhibitor panobinostat39. This evidence concerns the gene S100A4 and AL amyloidosis.